Akura Medical, a Shifamed portfolio company, today announced the closing of a $35 million Series B financing round.
Los Gatos, California-based Akura develops a differentiated approach to address the challenges of venous thromboembolism (VTE). The company earmarked the funds for supporting its FDA 510(k) clearance submission for the Akura mechanical thrombectomy platform. Other uses include supporting clinical trials for additional indications and scaling manufacturing capabilities.
The Capital Partnership (TCP) and Cormorant Asset Management led the financing round. The PA MedTech VC Fund, AMED Ventures, Lilly Asia Ventures, Unorthodox Ventures and Shifamed angel investors also participated.
Akura developed its thrombectomy platform as an easy-to-use, smaller bore system. The low-profile, steerable sheath allows physicians to bring the tip of the catheter directly to the proximal end of the clot without needing to cross the clot.
The platform features integrated aspiration and maceration technology as well. It incorporates intersecting jets to enable efficient removal of mixed morphology clots. Pressure sensors also provide real-time hemodynamic data to reduce the guesswork around case progress.
“The Akura thrombectomy platform is designed to provide large-bore catheter performance with a user-friendly system that will change how physicians approach thrombus removal in a clinically meaningful way,” said Murali Srivathsa, president and CEO, Akura Medical. “We thank our investors for their strong, ongoing support as we continue to execute and deliver on our commitment to advance our differentiated solution for VTE.”
